![](https://www.benzinga.com/next-assets/images/schema-image-default.png)
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc ACHL, a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company …